

MAIN CHARACTERISTICS OF ORAL ANTICOAGULANT THERAPY IN PATIENTS WITH ISCHEMIC HEART DISEASE

Amerova Dilafruz Abdukhalimovna*; **Ruziboeva Oyjamol Narzullaevna****;
Dadajanov Uktam Utkurovich***

*Assistant,
Department of Hematology,
Samarkand State Medical University,
Samarkand, UZBEKISTAN

**Assistant,
Department of Hematology,
Samarkand State Medical University,
Samarkand, UZBEKISTAN

***Assistant,
Department of Hematology,
Samarkand State Medical University,
Samarkand, UZBEKISTAN
Email id: Shahramaslanov97@gmail.com

DOI: 10.5958/2278-4853.2022.00374.3

ABSTRACT

Anticoagulants are drugs that prevent blood clots by acting on plasma coagulation factors. Anticoagulants mainly inhibit the appearance of fibrin filaments and contribute to the cessation of the growth of already formed thrombi, counteracting the effect of thrombin on fibrin. They also enhance the effect of endogenous fibrinolytic enzymes on blood clots.

KEYWORDS: *Clinical Significance, Unfractionated (Standard) Heparin, Anticoagulants, Direct Anticoagulant, a Synthetic Drug.*

REFERENCES:

1. Go A.S., Hylek E.M., Phillips K.A., et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285:2370-5. doi:10.1001/jama.285.18.2370.
2. Heeringa J., van der Kuip D.A., Hofman A., et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J. 2006;27:949-53. doi: 10.1093/eurheartj/ehi825.
3. Kirchhof P., Benussi S., Kotecha D., et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893-962. doi: 10.1093/eurheartj/ehw313.

4. Lip G.Y., Tse H.F., Lane D.A. Atrial fibrillation. *Lancet*. 2012;379:648-61. doi: 10.1016/S0140-6736(11)61514-6.
5. Lloyd-Jones D.M., Wang T.J., Leip E.P., et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. *Circulation*. 2004;110:1042-6. doi: 10.1161/01.CIR.0000140263.20897.42
6. Miyasaka Y., Barnes M.E., Gersh B.J., et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. *Circulation* 2006;114:119-25. doi: 10.1161/CIRCULATIONAHA.105.595140
7. Naccarelli G.V., Varker H., Lin J., Schulman K.L. Increasing prevalence of atrial fibrillation and flutter in the United States. *Am J Cardiol*. 2009;104:1534-9. doi: 10.1016/j.amjcard.2009.07.022.
8. Ringborg A., Nieuwlaat R., Lindgren P., et al. Costs of atrial fibrillation in five European countries: results from the Euro Heart Survey on atrial fibrillation. *Europace*. 2008;10:403-11. doi: 10.1093/europace/eun048.
9. Stewart S., Hart C.L., Hole D.J., McMurray J.J. Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study. *Heart*. 2001;86:516-21. doi: 10.1136/heart.86.5.516.
10. Wolowacz S.E., Samuel M., Brennan V.K., et al. The cost of illness of atrial fibrillation: a systematic review of the recent literature. *Europace*. 2011;13:1375-85. doi: 10.1093/europace/eur194.
11. Баркаган З. С., Мамот А. П., Тараненко И. А. и др. Основы пролонгированной профилактики и терапии тромбозов антикоагулянтами непрямого действия (показания, подбор доз, лабораторный мониторинг). – М., 2004.
12. Чазов Е. И., Беленков Ю. Н., Борисова Е. О. и др. Рациональная фармакотерапия сердечно-сосудистых заболеваний: Рук. для практикующих врачей / Под общ. ред. Е. И. Чазова, Ю. Н. Беленкова. – М.: Литтерра, 2006. – 971 с.
13. Viktorovna, B. I., Dzhumanovna, M. A., Gazkhanovna, M. A., & Turaevna, U. S. (2022). COMBINED GENETIC DISORDERS IN PATIENTS WITH COAGULOPATHY. *Международный журнал научной педиатрии*, (1), 23-29.
14. Abdiev, K. M., Madasheva, O. G., Ruziboeva, O. N., & Shomirzaev, K. M. (2021). COMPARATIVE EVALUATION OF NEW TREATMENTS FOR IMMUNE THROMBOCYTOPENIA. *NVEO-NATURAL VOLATILES & ESSENTIAL OILS Journal|NVEO*, 10160-10166.
15. Madasheva, A. G., & Zhuraeva, M. Z. (2019). Biochemical indicators and complex treatment of patients with psoriasis with therapeutic plasmapheresis. *Achievements of science and education*, 10(51), 78-82.
16. Халимова, Х. М., Раимова, М. М., & Матмуродов, Р. Ж. (2012). Влияние L-аргинина на когнитивные расстройства у больных хронической ишемией мозга с синдромом паркинсонизма. *Український хіміотерапевтичний журнал*, (3), 148-150.

Asian Journal of Multidimensional Research

ISSN: 2278-4853

Vol. 11, Issue 12, December 2022

SJIF 2022 = 8.179

A peer reviewed journal
